Novo Nordisk To 'Double Obesity Drug Sales by 2025'

Danish Group Says Year Off To ‘Good Start’

 
• By Sten Stovall
  
Group Plans Phase IIIa Oral Semaglutide Obesity Trial Dosed At 50mg • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business